A simple score of risk factors could help alert doctors to a likelihood of dangerous blood clots, called venous thromboembolism, forming as a side…
News
Allogene Therapeutics is launching the first clinical trial testing ALLO-715, its “off-the-shelf” CAR T-cell therapy, for people with multiple myeloma who failed…
The Committee for Medicinal Products for Human Use (CHMP), a branch of the European Medicines Agency (EMA), has recommended that Empliciti (elotuzumab)…
To ultimately drive immunotherapy discoveries in a complex cancer, the Multiple Myeloma Research Foundation (MMRF) has launched a precision medicine research initiative.
Adding Darzalex (daratumumab) to a treatment combination of Velcade (bortezomib), Revlimid (lenalidomide), and dexamethasone increased the proportion of newly diagnosed patients with multiple myeloma showing…
Sleep apnea can drive the development of aggressive multiple myeloma in mice resistant to the cancer, a study found, suggesting that the sleep disorder is…
In a continuing effort to support and advance early-phase multiple myeloma studies in the United Kingdom, Myeloma UK is launching a patient-focused research…
Janssen has asked the U.S. Food and Drug Administration (FDA) to approve a new subcutaneous (under-the-skin) formulation of Darzalex (daratumumab) as a…
A genomic rearrangement involving the immunoglobulin lambda (IgL) gene is predictive of resistance to immunomodulatory agents and poor outcomes among multiple myeloma patients, a new…
The U.S. Food and Drug Admnistration (FDA) has agreed to review Sanofi’s biologics license application (BLA) for its investigational antibody, isatuximab, as a potential…
